CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for AEterna Zentaris Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

AEterna Zentaris Inc.
315 Sigma Drive
Phone: (418) 652-8525p:418 652-8525 SUMMERVILLE, NB  29486  Canada Ticker: AEZSAEZS

Business Summary
Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company. The Company is developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (Macrilen, Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also leveraging the clinical and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD). The Company is engaged in the development of its therapeutic asset and has established a pre-clinical development pipeline to potentially address unmet medical needs across a number of indications, including neuromyelitis optica spectrum disorder (NMOSD), Parkinson's disease (PD), hypoparathyroidism and amyotrophic lateral sclerosis (ALS). Its therapeutic development pipeline includes AIM Biologicals, AEZS-150 and AEZS-130.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/202312/31/2022YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Non-Executive Independent Chairman of the Board Carolyn S.Egbert 5/1/2016 8/14/2012
President, Chief Executive Officer, Director and Managing Director - AEZS Germany KlausPaulini 10/4/2019 7/1/2019
Chief Financial Officer, Senior Vice President GiulianoLa Fratta 1/24/2022 1/24/2022
7 additional Officers and Directors records available in full report.

Business Names
Business Name
Aeterna Zentaris GmbH
Aeterna Zentaris, Inc.
AEZ
AEZS
ET8
Zentaris IVF GmbH

General Information
Number of Employees: 21 (As of 12/31/2022)
Outstanding Shares: 4,855,880 (As of 10/2/2023)
Shareholders: 234
Stock Exchange: TSE
Federal Tax Id: 000000000
Fax Number: (418) 948-9191


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, March 29, 2024